These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19579421)

  • 1. [Role and indication of GLP-1 analogues in the treatment of type 2 diabetes].
    Philippe J
    Rev Med Suisse; 2009 Jun; 5(206):1260-2, 1264-5. PubMed ID: 19579421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
    Fabreegas B
    Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
    Ross SA; Ballantine J
    Curr Med Res Opin; 2013 Dec; 29(12):1617-26. PubMed ID: 23971789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1 receptor agonists for type 2 diabetes.
    De Block CE; Van Gaal LF
    Lancet; 2009 Jul; 374(9683):4-6. PubMed ID: 19515414
    [No Abstract]   [Full Text] [Related]  

  • 7. [Exenatide: use in humans].
    Sierra-Ascencio ME; Ríos-Vaca A; Reza-Albarrán A
    Gac Med Mex; 2006; 142(6):483-91. PubMed ID: 17201111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
    Fernández-García JC; Colomo N; Tinahones FJ
    Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 receptor agonists today.
    Marre M; Penfornis A
    Diabetes Res Clin Pract; 2011 Sep; 93(3):317-27. PubMed ID: 21767888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel antihypertensive effect of exenatide, a GLP-1 agonist.
    Dandona P; Chaudhuri A; Dhindsa S
    Am J Hypertens; 2010 Mar; 23(3):228. PubMed ID: 20154655
    [No Abstract]   [Full Text] [Related]  

  • 13. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
    Consoli A; Di Biagio R
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases.
    Zoicas F; Droste M; Mayr B; Buchfelder M; Schöfl C
    Eur J Endocrinol; 2013 May; 168(5):699-706. PubMed ID: 23392214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 analogues for type 2 diabetes.
    Wilding JP; Hardy K
    BMJ; 2011 Feb; 342():d410. PubMed ID: 21325387
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of glucagon-like peptide-1 on the beta cell.
    Vilsbøll T
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?
    Nauck MA; Meier JJ
    Nat Rev Endocrinol; 2011 Apr; 7(4):193-5. PubMed ID: 21326278
    [No Abstract]   [Full Text] [Related]  

  • 18. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H; Erdmann E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD; Kim D; Weyer C
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New hypoglycemic agents in type 2 diabetes].
    Guerci B; Halter C
    Rev Prat; 2010 Apr; 60(4):495-503. PubMed ID: 20465123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.